BerGenBio has announced that Bemcentinib will be fast-tracked as a likely treatment for COVID-19 in a Phase II trial in a new U.K. national multi-center. This trial is poised to test the mettle of bemcentinib’s efficacy in treating the patients with COVID-19.
Reportedly, Department of Health and Social Care (DHSC) and U.K Research and Innovation (UKR) are funding the Accelerating COVID-19 Research & Development (ACCORD) platform. ACCORD has been playing an instrumental role in bringing together IQVIA, a clinical research company and prominent research expertise of the U.K. to offer a single, U.K.-wide clinical trial platform.
It is worth noting that the clinical trial will be underpinned by National Institute for Health Research to rev up test potential drugs with early stage clinical trials and use them in the COVID-19 studies that will run in large-scale, including the RECOVERY trial, which is said to be the largest randomized controlled clinical trail for the treatment of coronavirus.
CEO of BerGenBio Richard Godfrey expressed his delight to be part of the initiative which he dubbed “ground-breaking” partnership with the stakeholders. He appeared to be sanguine of the potential role Bemcentinib can play in the global effort to find an apt treatment choice for Coronavirus patients.
Godfrey has stated that dosing would be initiated in the next few days and would provide results as and when it is possible.
ACCORD clinical academic lead Professor Tom Wilkinson stated that they are leaving no stone unturned and will boost efficacious new treatments. Wilkinson was quoted saying that ACCORD will robustly test the likely new treatments through Phase 2 clinical trials into the NHS.
The innate national platform will help access the state-of-the-art resources and expertise of the National Institute for Health Research (NIHR) Respiratory Translational Research Collaboration globally.